HSHaiyun Shi

Haiyun Shi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Haiyun Shi has a total of 80 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Accelerometer‑Measured Physical Activity and Risk of All-Cause Mortality and Intestinal Surgery in Patients with Inflammatory Bowel Disease: A UK Biobank Longitudinal Study

    by Jiuyue Ma, Qi Sun, Minsi Zhou, Xinyi Xu, Yan Dang, Zi Ye, Chenyue Xu, Xueping Huang, Fang Xu, Han Lv, et al.

    Background: Although physical activity is known to be beneficial for chronic diseases, evidence regarding its role in the prognosis of inflammatory bowel disease (IBD) remains limited and relies primarily on subjective data. This study aimed to investigate the associations between device-measured physical activity and clinical outcomes in patients with IBD.Methods: A total of 1251 participants were sourced from the UK Biobank for analysis. Based on the wrist accelerometer data, daily movement behaviors were categorized into moderate-vigorous physical activity (MVPA), light physical activity (LIPA), sedentary behavior (SB), and sleep. Compositional data analysis and Cox proportional hazards regression were used to assess associations with all-cause mortality (n=1,251) and intestinal surgery (n=420). Sensitivity analyses excluded events occurring within the first two years of follow-up.Results: During follow-up, 85 deaths and 24 intestinal surgery events were recorded. Compared with the average activity composition of the cohort, reallocating time to achieve an additional 0.5 hr/day of MVPA was associated with a 24% lower risk of all-cause mortality (HR = 0.76, 95% confidence interval [CI]: 0.66-0.87, P<0.001). Furthermore, an additional 1.5 hr/day of total physical activity (combined MVPA and LIPA) reduced the risk of intestinal surgery by 20% (HR = 0.80, 95% CI: 0.72-0.90, P<0.001). In sensitivity analyses excluding early events (18 deaths and 8 surgeries), the associations remained robust: an additional 0.5 hr/day of MVPA reduced mortality risk by 19% (HR = 0.81, 95% CI: 0.70-0.94), and an additional 1.5 hr/day of physical activity reduced surgery risk by 20% (HR = 0.80, 95% CI: 0.72-0.90).Conclusion: Higher levels of objectively measured physical activity, particularly MVPA, are significantly associated with reduced risks of all-cause mortality and intestinal surgery in patients with IBD. These findings highlight the prognostic value of promoting physical activity in IBD management.

  • Open Access

    Risk factors and prediction model for post-polypectomy metachronous colorectal adenoma

    by Jiuyue Ma, Qian Zhang, Jiayi Su, Yun Wang, Wenkun Li, Minsi Zhou, Kuiliang Liu, Haiyun Shi, Jing Wu

    Endoscopic resection of colorectal adenomas helps reduce colorectal cancer mortality. However, post-polypectomy metachronous adenomas may reduce the sufficiency of colonoscopy scanning. To explore the risk factors for post-polypectomy metachronous colorectal adenoma and establish a risk prediction model. This retrospective cohort study included patients who underwent colonoscopy at Beijing Friendship Hospital from January 2013 to January 2023. Data on patients' demographics, laboratory results, colonoscopy findings, and pathology reports were collected. The enrolled patients were randomly divided into a training set and a validation set in a 7:3 ratio. LASSO analysis was employed to identify risk factors for metachronous adenomas. Based on these risk factors, a Cox regression model was used to create a risk prediction model. The C-index was calculated to assess the model's prediction accuracy, while time-dependent ROC (td-ROC) curves and calibration curves evaluated model predictive performance. A Decision Curve Analysis (DCA) was conducted to assess clinical utility. A total of 523 patients meeting the inclusion and exclusion criteria were enrolled and randomly divided into a training set (n = 366) and a validation set (n = 157). Twenty-one clinical and pathological features were included in the LASSO regression analysis. Among these, age, gender, baseline adenoma size, baseline adenoma location, baseline pathological grade, history of hypertension, and serum LDL level were included in the multivariable Cox regression analysis, leading to the establishment of a visualized nomogram model. The C-index of the predictive model was 0.729 (95% CI: 0.686, 0.772) in the training set and 0.724 (95% CI: 0.667, 0.781) in the validation set. The time-dependent ROC curve and calibration curve indicated good reliability of the model, and the DCA curve suggested satisfactory clinical utility. An online webserver was also constructed to visualize the model and facilitate the calculation of metachronous adenoma risk for clinicians (URL: https://colorectal-metachronous-adenoma-prediction.shinyapps.io/DynNomapp/). A total of 7 risk factors for post-polypectomy metachronous adenoma were identified. A risk prediction model that possesses good prediction accuracy and good clinical utility was established, providing a reliable tool for patient risk stratification.

  • Open Access

    Impact of Diet and Drugs on Fecal Lachnoclostridium Gene Marker ( m3 ) in Non‐Invasive Diagnosis of Colorectal Neoplasia

    by Min Dai, Louis H. S. Lau, Haiyun Shi, Yang Sun, Xiaobo Li, Mengbin Li, Hui Wang, Raphaela I. Lau, Jessie Q. Y. Liang, Francis K. L. Chan, et al.

    Background: A novel bacterial gene marker, Lachnoclostridium ( m3 ), has potential for non‐invasive diagnosis of colorectal cancer (CRC) and adenoma. Aim: This study aims to determine the diagnostic performance of m3 in a multi‐center cohort and to examine the effect of diet and drugs on fecal m3 in subjects with colorectal neoplasia. Methods: In a prospective cohort study, we included 2563 subjects (330 CRC, 1119 adenomas, and 1114 controls) from two independent cohorts from Hong Kong and five cities in the Chinese mainland. Stool samples were collected before colonoscopies and bowel preparation. Dietary information was collected using a qualitative dietary questionnaire. Fecal m3 was measured using quantitative PCR (qPCR). Receiver operating characteristic (ROC) curves were used to evaluate the diagnostic performance of fecal m3 . The impact of diet and drugs on fecal m3 was investigated using in vitro experiments and multivariate analysis by logistic regression. Results: Fecal m3 could significantly discriminate CRC and advanced adenoma (AA) from normal controls, with areas under the receiver operating characteristic curve (AUROC) of 0.701 and 0.604 (both p < 0.001), respectively. Three types of dietary components (meat, vegetables, and oil) and 15 drugs did not affect fecal m3 levels in vitro. In multivariate analysis, after adjusting for clinical factors, diet and drugs did not have a significant impact on fecal m3 levels in subjects with colorectal neoplasia. Conclusion: Fecal m3 levels and diagnostic performance were not influenced by diet and drugs. It can be considered a promising and reliable non‐invasive diagnostic biomarker for colorectal neoplasia.


  • Open Access

    Plasma proteomic markers predict risk for bowel resection in inflammatory bowel disease: a retrospective cohort study

    by Xinyi Xu, Chenyue Xu, Na Zeng, Qi Sun, Fang Xu, Jiuyue Ma, Xueping Huang, Minsi Zhou, Jing Sun, Shengtao Zhu, et al.

    Background: Bowel resection is required in up to 27% of inflammatory bowel disease (IBD) patients due to severe complications. Identifying reliable predictors for future surgery is crucial for risk stratification and management. Materials and Methods: We retrospectively analyzed UK Biobank data of IBD patients with plasma proteomics measured using the Olink platform. A Random Survival Forest (RSF) model was used to evaluate the predictive performance of inflammatory proteins for surgical risk. The concordance index (C-index) compared Olink-based and conventional clinical models. A predicted risk score quantified individual surgery risk, and Kaplan-Meier analysis assessed differences in surgery-free survival between high- and low-risk groups. Cox proportional hazards models verified the independent predictive value of proteomics. Results: Among 915 patients with IBD, 81 cases underwent bowel resection during follow-up. The RSF model using Olink proteins achieved a superior C-index compared to conventional markers (0.784 vs 0.543, P < 0.01). Key predictors included IL15, PAPPA, and PIK3AP1. Patients with a higher predicted risk score had a significantly higher surgery risk ( P < 0.0001). The predicted risk score remained an independent predictor for surgery risk [adjusted HR: 0.83, 95% confidence interval (CI): 0.81–0.86]. The net reclassification analysis demonstrated improved patient-level stratification by proteomic features beyond standard clinical predictors (net reclassification improvement: 0.096, 95% CI: 0.008–0.257, P = 0.027). Conclusion: Plasma proteomic markers demonstrated superior predictive performance over traditional markers in assessing future bowel resection risk in IBD. Incorporating proteomics into clinical practice could enhance risk stratification and inform early interventions to reduce surgical burdens.


  • Open Access

    Fecal microbiota composition and function are associated with anxiety and depression in patients with inflammatory bowel disease

    by Zhan Wang, Minsi Zhou, Yan Dang, Xueping Huang, Chenyue Xu, Fang Xu, Xinyi Xu, Peng Li, Shutian Zhang, Haiyun Shi, et al.

    Background and aims: Increasing prevalence of anxiety and depression are found in patients with inflammatory bowel disease (IBD). Altered gut microbiome may affect the brain, resulting in psychiatric symptoms. We aimed to analyze the feature of gut microbiota in IBD patients with anxiety or depression. Methods: Anxiety and depression symptoms were assessed by the Hospital Anxiety and Depression Scale (HADS). Stool samples were collected from IBD patients, and the 16S rRNA sequencing was used to detect fecal microbiota. Metabolites were detected by Liquid Chromatography-Mass Spectrometry (LC-MS). Results: Among the involved IBD patients (n = 59), 28.81% had anxiety and 33.90% had depression. Linear discriminant analysis Effect Size (LEfSe) (LDA > 3.0) revealed that 4 genera ( Klebsiella, Alloprevotella, Barnesiella, Bacillus ) were enriched, while Sellimonas was depleted in the anxiety group. Enrichment of 2 genera ( Ruminococcus, Barnesiella ) were found in the depression group. In the anxiety group, valine, leucine and isoleucine degradation was enriched in fecal microbiota, with upregulation of 3-methyl-2-oxobutanoic acid involved in the above pathway. In the depression group, butanoate metabolism was enriched in fecal microbiota, with alpha-ketoglutaric acid involved. Lysine degradation were enriched in fecal microbiota, with pipecolic acid involved. Primary bile acid biosynthesis was depleted in fecal microbiota, with glycocholic acid involved. Pearson correlation analysis revealed a positive correlation between Alloprevotella and 3-methyl-2-oxobutanoic acid in the anxiety group. In patients with both anxiety and depression, four genera ( Subdoligranulum, Alloprevotella, Christensenellaceae R-7 group, Barnesiella ) were positively correlated with alpha-ketoglutaric acid. Conclusion: In this study, the alteration of composition of fecal microbiota was identified, and differential genus associated with IBD patients with anxiety or depression or both were explored. Change in function of microbiota was also discovered by the detection of differential pathways and fecal metabolites, which were associated with IBD patients with anxiety or depression or both.


  • Open Access

    Identification of Biomarkers for Treatment Escalation of Ulcerative Colitis Based on Untargeted Metabolomics and Machine Learning Algorithms: A Prospective Cohort Study

    by Muzhou Han, Hao Wang, Siying Zhu, Peng Li, Haiyun Shi, Yongdong Wu

    INTRODUCTION: Biomarkers to guide clinical decision making in active ulcerative colitis (UC) patients are urgently needed. This study aims to identify metabolites associated with UC treatment escalation and establish prediction models based on untargeted metabolomics and machine learning algorithms. METHODS: Liquid chromatography-mass spectrometry-based untargeted metabolomics analysis was performed on 88 plasma samples (44 active UC patients requiring treatment escalation and 44 active UC patients not requiring treatment escalation). Univariate and multivariate analyses were applied to identify metabolic biomarkers for UC treatment escalation. Metabolic pathway enrichment analysis was performed to reveal the disturbed metabolic pathways related to UC treatment escalation. Four machine learning algorithms, including Support Vector Machine, Random Forest, k-Nearest Neighbor, and logistic regression were used to build diagnostic models for UC treatment escalation. RESULTS: Nine significantly differential metabolites were identified as the candidate biomarkers for UC treatment escalation. Pathway analysis revealed that phenylalanine metabolism and ether lipid metabolism are the disturbed metabolic pathways related to treatment escalation. The protein-metabolite interaction network identified 21 proteins are associated with 9 treatment escalation related metabolites. The areas under the receiver operating characteristic curve of the Support Vector Machine, Random Forest, k-Nearest Neighbor, and logistic regression models based on metabolic biomarkers were 0.923, 0.966, 0.897 and 0.803, respectively. DISCUSSION: The plasma metabolome represents a promising source of biomarkers for the prediction of treatment escalation in active UC. Metabolic biomarkers, combined with machine learning algorithms, could be efficient for risk assessment and early identification of UC treatment escalation.


  • Open Access

    Plasma inflammation-related proteins associated with anxiety and depression disorders in IBD patients

    by Min Si Zhou, Wan Ru Zhang, Yan Dang, Fang Xu, Chen Yue Xu, Zhan Wang, Chun Sai Er Wang, Si Ying Zhu, Peng Li, Jing Wu, et al.

    Up to 25-35% of patients with inflammatory bowel disease (IBD) suffer from anxiety or depression. Mood disorders are correlated with activated inflammatory response. However, changes of inflammation-related proteins in IBD patients with anxiety or depression disorders are still unclear. We aimed to depict the plasma proteomics characteristics of IBD patients with anxiety or depression. Adult patients diagnosed with IBD were prospectively enrolled, and the clinical data were obtained. The Hospital Anxiety and Depression Scale (HADS) was used to assess anxiety or depression levels. OLINK panel (Target 96 Inflammation) was used to quantify the plasma levels of inflammation-related proteins. Among the involved 142 IBD patients (median age 39.5, 42.96% female), 41 were comorbid with anxiety or depression symptoms. The levels of anxiety and depression symptoms in active phase group were significantly higher than those in quiescent group (P = 0.020). The anxiety and depression levels of IBD patients were positively correlated with fatigue levels (r = 0.713, P < 0.001), and negatively correlated with sleep quality (r = 0.499, P < 0.001) and quality of life (r =-0.692, P < 0.001). Plasma levels of 92 inflammation-related proteins were measured in 61 IBD patients. Up-regulated levels of fibroblast growth factor 23 (FGF-23) were found in IBD patients with anxiety or depression disorders, with an area under the curve (AUC) of 0.67(95%CI:0.53–0.81, P = 0.031). The plasma levels of C-C motif chemokine 20 (CCL20) and C-X-C motif chemokine 1 (CXCL1) were up-regulated in IBD patients with anxiety or depression, respectively, and the corresponding AUCs were 0.68 (95%CI:0.54–0.82, P = 0.036) and 0.70(95%CI:0.56–0.84, P = 0.017). Correlation analysis showed that the levels of anxiety and depression symptoms in IBD patients were negatively correlated with plasma Delta/Notch-like epidermal growth factor-related receptor (DNER) (r=-0.253, P = 0.047) and interleukin-8 (IL-8) (r=-0.275, P = 0.031) levels, and were positively correlated with the plasma levels of CXCL1 (r = 0.290, P = 0.022) and FGF-23 (r = 0.290, P = 0.022). In addition, negative correlation was found between plasma DNER levels and Mayo clinical scores in ulcerative colitis (UC) patients (r=-0.464, P = 0.001). Mood disorders are closely related to disease flare of IBD patients. The increasing levels of anxiety and depression in IBD patients are accompanied by graver fatigue, worse sleep quality and lower quality of life. Inflammation-related immune regulation is associated with the development of emotional disorders in IBD patients.


  • Open Access

    Gut microbiome signatures predict 5-ASA efficacy in ulcerative colitis

    by Yan Dang, Xinyi Xu, Jiuyue Ma, Minsi Zhou, Chenyue Xu, Xueping Huang, Fang Xu, Zhan Wang, Haiyun Shi, Shutian Zhang


  • Open Access

    NELFCD Promotes Colon Cancer Progression by Regulating the DUSP2–p38 Axis

    by Weiwei Dai, Min Zhu, Yujing Sun, Baohong Xu, Guorong Ma, Haiyun Shi, Peng Li

    Background: To investigate the significance of the negative elongation factor complex member C/D (NELFCD) in colon cancer progression. Methods: Immunohistochemistry staining, Western blot analysis, and real-time quantitative polymerase chain reaction (RT-qPCR) were used to quantify the protein/gene levels. NELFCD-protein arginine methyltransferase 5 (PRMT5) interaction was determined by co-immunoprecipitation assay. A chromatin immunoprecipitation (ChIP) assay was performed to determine the interaction between the promoter region of dual specificity phosphatase 2 (DUSP2), NELFCD, and PRMT5. Cell growth and cell cycle progression were assessed using the cell counting kit-8 proliferation assay, colony formation assay, and/or flow cytometry. Results: NELFCD was upregulated in colon cancer and promoted cancer cell growth. In colon cancer cells, the expression of NELFCD was negatively correlated with DUSP2 expression. The RNA sequencing results indicated that genes in the mitogen-activated protein kinase (MAPK) signaling pathway as well as DUSP2 were affected by NELFCD. The ChIP sequencing results revealed that DUSP2 and genes in the MAPK signaling pathway are direct targets of NELFCD. ChIP assay verified that PRMT5 is enriched at the promoter region of DUSP2 and that NELFCD overexpression promoted this enrichment. A co-immunoprecipitation assay demonstrated that NELFCD was bound to PRMT5, functioning as a macromolecular complex. Conclusions: This study suggests that NELFCD promotes the progression of colon cancer by recruiting PRMT5 to inhibit DUSP2 expression, which subsequently activates the p38 signaling pathway. Targeting the NELFCD–DUSP2–p38 signaling axis may be a promising therapeutic intervention for patients suffering from NELFCD-amplified tumors.

  • Clinical performance of a particle enhanced turbidimetric immunoassay (PETIA) for detecting fecal calprotectin

    by Tieshan Wang, Wei Wang, Siying Zhu, Minsi Zhou, Peng Li, Jing Wu, Shutian Zhang, Haiyun Shi

    Particle-enhanced turbidimetric immunoassay (PETIA) is a new measurement procedure for detecting fecal calprotectin (FC). We aimed to investigate the accuracy and clinical performance of PETIA for FC. We assessed the accuracy of PETIA for FC measurements through concordance analysis, Passing-Bablok regression and Bland-Altman analysis, using enzyme-linked immunosorbent assay (ELISA) as the reference. To evaluate the clinical performance of PETIA, the FC levels of individuals with significant and non-significant bowel diseases were compared. The receiver operating characteristic (ROC) analysis was performed to determine the appropriate cut-off value of FC detected by PETIA for discriminating subjects with significant and non-significant colorectal lesions. Of the 413 cases analyzed, 340 (82.3%) were concordant between PETIA and ELISA. No significant discordance was observed. There was a good agreement (y = -7.710+0.957x) between PETIA and ELISA for detecting FC. The FC level detected by PETIA in patients with significant bowel diseases (159.1 [31.3, 821.0] mu g/g) was significantly higher than that of subjects with non-significant bowel diseases (10.3 [4.2, 38.5] mu g/g) (p < 0.001). The AUC of FC for identifying significant bowel diseases detected by PETIA was 0.82 (p < 0.001). With a cut-off value of 77.6 mu g/g, the specificity and positive predictive value were 92.2% and 97.1%, respectively. The PETIA for FC measurement showed good clinical performance for detecting bowel diseases.